Doha declaration implications for biotech law

Introduction

The Doha Declaration on the TRIPS Agreement and Public Health was adopted by the World Trade Organization (WTO) Ministerial Conference on 14 November 2001. It clarified that intellectual property protection should not prevent WTO members from taking measures to protect public health and promote access to medicines. Although primarily concerned with pharmaceutical products, its principles have important implications for biotechnology, including vaccines, biologic medicines, genetic technologies and other life-science innovations.

The Declaration recognises that intellectual property rights must be interpreted in a manner supportive of public health. It is particularly important for developing countries because biotechnology products are often protected by patents, making access dependent on licensing, manufacturing capacity and affordability.

Legal framework and major provisions

The Doha Declaration interprets the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), 1994. It confirms that TRIPS should not prevent members from protecting public health and promoting access to medicines for all.

Article 4 recognises the right of WTO members to grant compulsory licences and determine the grounds on which such licences are granted. This allows governments to authorise the production or use of patented inventions without the patent holder's consent, subject to applicable conditions.

Article 5 confirms that each member has the freedom to determine what constitutes a national emergency or other circumstances of extreme urgency. Public-health emergencies, including epidemics, may qualify.

Article 6 recognises the right of members to establish their own regimes for the exhaustion of intellectual property rights, subject to relevant TRIPS provisions. This supports the possibility of parallel imports under national law.

Article 7 clarifies that TRIPS provisions should be interpreted in light of their objectives, including technological innovation, transfer and dissemination of technology, and social and economic welfare.

The 2003 WTO General Council Decision, later incorporated into TRIPS Article 31bis, addressed countries lacking sufficient pharmaceutical manufacturing capacity by creating a mechanism for importing medicines produced under compulsory licences elsewhere.

Implications for biotechnology law

1. Compulsory licensing of biotechnology products

Biotechnology inventions, including vaccines, therapeutic proteins and diagnostic technologies, may receive patent protection. However, during public-health emergencies, governments may use compulsory licensing to facilitate production and supply.

In India, Sections 84 and 92 of the Patents Act, 1970 provide important compulsory-licensing mechanisms. Section 92 allows the Central Government to issue a notification in circumstances such as national emergency, extreme urgency or public non-commercial use.

2. Access to vaccines and biologic medicines

The Declaration supports policies that balance patent protection with public-health requirements. This is particularly relevant to vaccines, monoclonal antibodies and other biologics, where manufacturing may require specialised technology and technical knowledge.

However, compulsory licensing alone may not ensure access. Biotechnology products can involve complex manufacturing processes, regulatory approvals, trade secrets and specialised infrastructure. Technology transfer and manufacturing cooperation are therefore also important.

3. Research and technological development

The Declaration supports a balanced intellectual property system that encourages innovation while promoting access. Biotechnology researchers and manufacturers benefit from a legal environment that protects inventions without unnecessarily restricting scientific progress.

India's Patents Act, particularly Sections 3(d), 47, 84 and 107A, contributes to this balance. Section 3(d) restricts patents for certain new forms of known substances unless enhanced efficacy is demonstrated, while Section 107A provides specified exceptions, including regulatory-use activities.

4. Public-health emergencies and international cooperation

The Declaration provides flexibility for countries facing epidemics and other serious health emergencies. It supports international cooperation to improve access to essential medicines and biotechnology products.

The COVID-19 pandemic demonstrated the importance of balancing patent rights, manufacturing capacity, voluntary licensing and equitable distribution. The WTO's 2022 Ministerial Decision on the TRIPS Agreement and COVID-19 Vaccines further addressed certain patent-related flexibilities for vaccine production and export.

Important judicial decisions and case laws

1. Novartis AG v. Union of India (2013)

The Supreme Court examined Section 3(d) of the Patents Act in relation to the patent application for a modified form of the cancer medicine imatinib mesylate. The Court rejected the application because the claimed invention did not establish the required enhancement in therapeutic efficacy.

Legal significance: The decision demonstrates India's approach to preventing unjustified patent extensions and maintaining access to important medicines. It reflects principles consistent with the public-health objectives underlying the Doha Declaration.

2. Bayer Corporation v. Union of India (2014)

The Bombay High Court considered the compulsory licence granted to Natco Pharma for Bayer's patented cancer medicine, Nexavar. The Court upheld the compulsory-licensing decision.

Legal significance: The case illustrates how Indian patent law can balance patent-holder interests with affordability and public access to essential medicines.

3. F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (2008)

The Delhi High Court considered a patent dispute involving the cancer medicine erlotinib. The litigation addressed patent protection and the public interest in access to medicines.

Legal significance: The decision illustrates the tension between pharmaceutical patent rights and public-health considerations, although it did not directly interpret the Doha Declaration.

4. Bayer Corporation v. Natco Pharma Ltd. (2013)

The Intellectual Property Appellate Board examined India's first compulsory licence granted under Section 84 of the Patents Act for Nexavar. It considered affordability, reasonable requirements of the public and working of the patent in India.

Legal significance: The decision provides an important illustration of how compulsory licensing can be applied to improve access to patented medicines.

Challenges and conclusion

The Doha Declaration provides significant legal flexibility, but its implementation in biotechnology faces practical difficulties. Biologic medicines often require complex manufacturing facilities, technical expertise, regulatory compliance and access to specialised materials. Patent licensing may not automatically provide access to confidential manufacturing knowledge or trade secrets.

Furthermore, governments must balance public-health needs with incentives for research and development. Excessive uncertainty concerning patent protection may affect investment, while overly restrictive intellectual property rules may limit access to essential treatments.

In conclusion, the Doha Declaration establishes an important principle for biotechnology law: intellectual property protection must operate alongside public-health objectives. Its influence is visible in compulsory licensing, access-to-medicine policies and international technology cooperation. Indian judicial decisions, particularly Novartis and Bayer, demonstrate how domestic patent law can support this balance while preserving the broader objectives of innovation and public welfare.